Shopping Cart
- Remove All
- Your shopping cart is currently empty
Giredestrant (GDC-9545) potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity. Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $139 | In Stock | |
5 mg | $289 | In Stock | |
10 mg | $463 | In Stock | |
25 mg | $868 | In Stock | |
50 mg | $1,390 | In Stock | |
100 mg | $2,180 | In Stock | |
200 mg | $2,960 | In Stock | |
1 mL x 10 mM (in DMSO) | $332 | In Stock |
Description | Giredestrant (GDC-9545) potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity. Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. |
In vitro | The highly potent in vivo efficacy of Giredestrant likely arises due to the particular combination of high binding potency, full suppression of ER signaling, and an improved DMPK profile.Giredestrant (GDC-9545) is a novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. |
Alias | GDC-9545 |
Molecular Weight | 522.55 |
Formula | C27H31F5N4O |
Cas No. | 1953133-47-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (191.37 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.